NRAS and melanoma: Overall survival was significantly correlated with increased age (r = 0.25, p < 0.10), and was significantly higher in patients with melanoma at stage M1a stage, NRAS mutation, better ECOG performance status, an LDH below the ULN, and fewer than three metastatic sites (Table 4).